Elinzanetant versus placebo for menopausal vasomotor symptoms

Phase 3, randomised, double-blind trial in vasomotor symptoms comparing Elinzanetant then elinzanetant with Placebo then elinzanetant (2 arms). Primary endpoints: Mean change in frequency of moderate to severe hot flashes from baseline to Week 4, Mean change in frequency of moderate to severe hot flashes from baseline to Week 12 and 2 more. Started May 2022; status: active, not recruiting.